HemoRea
ActiveSummary
HemoRea has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2,500 and a net result of €39,687. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 10% of 16754 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability100=
Solvency30▲+1
Growth58=
Track record94
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Human health activities (NACE 86)
about 87% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
5%
Return on assets
78.8%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 10% of 16754 sector peers (2025).
NBB · sector comparisonPosition among 16754 sector peers
Solvency
better than 10%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-07-2026, 9 days ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
9 d early
2024
8 d early
2023
8 d early
2022
21 d early
2021
16 d late
2020
11 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 7 days before the deadline; the sector median for financial year 2024 is 7 days before the deadline, and 36% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
28-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, micro schema
Equity
€2,500=
2024 · €2,500
Total assets
€50,378▼ 17.0%
2024 · €60,703
Net result
€39,687▲ 61.8%
2024 · €24,531
Working capital
€554▲ 141%
2024 · €230
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result€12,037▼ 55.7%€16,638▲ 38.2%€35,646▲ 114%€34,291▼ 3.8%€54,030▲ 57.6%
Net result€8,412below the sector's middle half▼ 58.5%€11,017below the sector's middle half▲ 31.0%€25,171within the sector's middle half▲ 128%€24,531within the sector's middle half▼ 2.5%€39,687within the sector's middle half▲ 61.8%
Equity€30,372below the sector's middle half▲ 33.4%€41,388below the sector's middle half▲ 36.3%€2,500below the sector's middle half▼ 94.0%€2,500below the sector's middle half=€2,500below the sector's middle half=
Total assets€41,013below the sector's middle half▲ 37.0%€47,711below the sector's middle half▲ 16.3%€77,207below the sector's middle half▲ 61.8%€60,703below the sector's middle half▼ 21.4%€50,378below the sector's middle half▼ 17.0%
Debt€10,641▲ 48.4%€6,323▼ 40.6%€74,707▲ 1,082%€58,203▼ 22.1%€47,878▼ 17.7%
Working capital€30,372within the sector's middle half▲ 33.4%€41,652within the sector's middle half▲ 37.1%€2,682below the sector's middle half▼ 93.6%€230below the sector's middle half▼ 91.4%€554below the sector's middle half▲ 141%
Solvency74.1%within the sector's middle half▼ 2.0pp86.7%above the sector's middle half▲ 12.7pp3.2%below the sector's middle half▼ 83.5pp4.1%below the sector's middle half▲ 0.9pp5.0%below the sector's middle half▲ 0.8pp
Current ratio3.85within the sector's middle half▼ 0.327.87above the sector's middle half▲ 4.021.04below the sector's middle half▼ 6.841.00below the sector's middle half▼ 0.031.01below the sector's middle half▲ 0.01
Return on assets (ROA)20.5%within the sector's middle half▼ 47.2pp23.1%within the sector's middle half▲ 2.6pp32.6%within the sector's middle half▲ 9.5pp40.4%above the sector's middle half▲ 7.8pp78.8%above the sector's middle half▲ 38.4pp
above
within
below
the middle half (P25 to P75) of NACE 86, Human health activities, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 58% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €50,378
Fixed assets
€1,946 ▼ 20.2%
Current assets
€48,432 ▼ 16.9%
Equity and liabilities €50,378
Equity
€2,500 =
Debt
€47,878 ▼ 17.7%
Debt's share of the balance-sheet total falls from 95.9% to 95.0%. Debt is lower.
Key figures and ratios
EBITDA
€54,523▲
2024 · €34,319
Cash flow
€40,181▲
2024 · €24,560
Debt to equity
19.15▼
2024 · 23.28
Interest coverage
619.58▲
2024 · 53.42
Debt ≤ 1 year
€47,878▼
2024 · €58,033
Income taxes
€14,255▲
2024 · €9,117
A ratio outside any meaningful range has been withheld (balance sheet total €50,378, equity €2,500).
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 2,151 companies that looked in July 2024 the way this one looks now, 1.6% went bankrupt within 24 months and 96% are still going.
- Micro
- 5 to 10 years old
- solvency under 10%
- a profit of 5% of the balance sheet or more
1.6%
went bankrupt
2.2%
stopped otherwise
96%
still going
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.2% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.7% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 2,151 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €10,325 | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | - | - | €28 | €494 | ▲ 1,643% |
| Other operating charges640/8 | €2,778 | €596 | €656 | €673 | €352 | ▼ 47.6% |
| Gross operating margin9900 | €14,816 | €17,234 | €36,302 | €34,992 | €54,875 | ▲ 56.8% |
| Operating profit (loss)9901 | €12,037 | €16,638 | €35,646 | €34,291 | €54,030 | ▲ 57.6% |
| Financial charges65/66B | €956 | €1,097 | €819 | €642 | €88 | ▼ 86.3% |
| Recurring financial charges65 | €956 | €1,097 | €819 | €642 | €88 | ▼ 86.3% |
| Profit (loss) for the period before taxes9903 | €11,082 | €15,541 | €34,827 | €33,648 | €53,942 | ▲ 60.3% |
| Income taxes67/77 | €2,670 | €4,525 | €9,657 | €9,117 | €14,255 | ▲ 56.4% |
| Profit (loss) for the period9904 | €8,412 | €11,017 | €25,171 | €24,531 | €39,687 | ▲ 61.8% |
| Profit (loss) for the period to be appropriated9905 | €8,412 | €11,017 | €25,171 | €24,531 | €39,687 | ▲ 61.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €41,013 | €47,711 | €77,207 | €60,703 | €50,378 | ▼ 17.0% |
| Fixed assets21/28 | - | - | - | €2,440 | €1,946 | ▼ 20.2% |
| Tangible fixed assets22/27 | - | - | - | €2,440 | €1,946 | ▼ 20.2% |
| Plant, machinery and equipment23 | - | - | - | €2,440 | €1,946 | ▼ 20.2% |
| Current assets29/58 | €41,013 | €47,711 | €77,207 | €58,264 | €48,432 | ▼ 16.9% |
| Amounts receivable within one year40/41 | €2,767 | €3,975 | €3,975 | €24,000 | - | - |
| Trade receivables40 | €2,500 | - | - | €24,000 | - | - |
| Other amounts receivable41 | €267 | €3,975 | €3,975 | - | - | - |
| Cash at bank and in hand54/58 | €38,246 | €43,736 | €72,989 | €34,264 | €48,132 | ▲ 40.5% |
| Deferred charges and accrued income490/1 | - | - | €242 | - | €299 | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €41,013 | €47,711 | €77,207 | €60,703 | €50,378 | ▼ 17.0% |
| Equity10/15 | €30,372 | €41,388 | €2,500 | €2,500 | €2,500 | = |
| Contributions10/11 | €2,500 | €2,500 | €2,500 | €2,500 | €2,500 | = |
| Profit (loss) carried forward14 | €27,872 | €38,888 | - | - | - | - |
| Amounts payable17/49 | €10,641 | €6,323 | €74,707 | €58,203 | €47,878 | ▼ 17.7% |
| Amounts payable within one year42/48 | €10,641 | €6,060 | €74,525 | €58,033 | €47,878 | ▼ 17.5% |
| Trade debts44 | - | €424 | €2,424 | €25,675 | €1,513 | ▼ 94.1% |
| Suppliers440/4 | - | €424 | €2,424 | €25,675 | €1,513 | ▼ 94.1% |
| Taxes, remuneration and social security45 | €10,081 | €3,420 | €16,015 | €9,703 | €7,708 | ▼ 20.6% |
| Taxes450/3 | €10,081 | €2,920 | €15,515 | €9,703 | €7,708 | ▼ 20.6% |
| Remuneration and social security454/9 | - | €500 | €500 | - | - | - |
| Other amounts payable47/48 | €560 | €2,216 | €56,086 | €22,656 | €38,658 | ▲ 70.6% |
| Accrued charges and deferred income492/3 | - | €263 | €182 | €170 | - | - |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €8,412 | €11,017 | €25,171 | €24,531 | €39,687 | ▲ 61.8% |
| + Depreciation and write-downs630 | - | - | - | €28 | €494 | ▲ 1,643% |
| Operating cash flow (approximation) | €8,412 | €11,017 | €25,171 | €24,560 | €40,181 | ▲ 63.6% |
| Investment in fixed assets (approximation) | - | - | - | - | €0 | - |
| Change in cash | - | €5,490 | €29,254 | -€38,726 | €13,869 | ▲ 136% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
22-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2020net €39,687 ▲61.8%
Operating result €54,030, net result €39,687, both a record.
23-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
23-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
10-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Liquidity doublescurrent ratio 7.87
Current ratio from 3.85 to 7.87; short-term debt falls from €10,641 to €6,060.
16-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 16 days late
2021
31-12
Financial
Weakest financial yearnet €8,412 ▼58.5%
Net result drops to €8,412, the lowest in the series; recovery starts the following year.
20-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Namur · 1 establishment unit since 2020
Ground area
853 m²
Building footprint
108 m²
Volume, LiDAR
624 m³
Parcel 92322D0366/00E003, Wallonia · tallest building 7.0 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
HemoRea SRL
since 20202.308.450.639
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92322D0366/00E003 | Wallonia | 852 m² | 1 · 108 m² | 7.0 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
DOCTEUR DIMITRIADOU Anastasia
BE 0647.564.872
Ukkel · Eq €2,500
DR. DELPHINE VEROUGSTRAETE - URGENTIEARTS
BE 0732.724.439
Deinze · Eq €2,500
DR. BARBARA VERSYCK
BE 0735.854.074
Schilde · Eq €2,500
Maarten De Meulenaere – Kinder- en Jeugdpsychiater
BE 0736.407.964
Destelbergen · Eq €2,500
AnestAlgo
BE 0736.493.878
Kasterlee · Eq €2,500
Of 16,631 companies in sector 86220 we hold annual accounts for 7,985. 1,059 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded06-10-2020
Fiscal year end31-12
Activities, NACEBEL 2025
86220Specialist medical practice
Contact
E-mail
nathalielayios@yahoo.fr
Phone
+32474692898
E-invoicing
Reachable via Peppol
Peppol ID
0208:0755776191
Also
9925:BE0755776191
Registered
17-11-2025
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.